WHO ICTRP trial
A study for autologous anti-CD19 (mice derived) chimeric antigen receptor T…
ChiCTR1900022216 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR1900022216 |
|---|---|
| Public title | A study for autologous anti-CD19 (mice derived) chimeric antigen receptor T cells treating refractory or relapsed B acute lymphoblastic leukemia |
| Scientific title | A study for autologous anti-CD19 (mice derived) chimeric antigen receptor T cells treating refractory or relapsed B acute lymphoblastic leukemia |
| Primary sponsor | Beijing Boren Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Observational study |
| Phase | 0 |
| Countries | China |
| Conditions | Relapsed or refractory B acute lymphoblastic leukemia |
| Interventions | treatment group:D19-cart cell immunotherapy |
| Registration date | Mar 30, 2019 |
| Target size | treatment group:200 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: